Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
BACKGROUNDCOVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined.METHODSThis secondary analysis correlated donor and recipient antibody levels to hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double-blind, randomized clinical trial that compared CCP to control plasma. The majority of COVID-19 CCP arm hospitalizations (15/17, 88%) occurred in this unvaccinated, seronegative subgroup. A functional cutoff to delineate recipient high versus low posttransfusion antibody levels was established by 2 methods: (i) analyzing virus neutralization-equivalent anti-Spike receptor-binding domain immunoglobulin G (anti-S-RBD IgG) responses in donors or (ii) receiver operating characteristic (ROC) curve analysis.RESULTSSARS-CoV-2 anti-S-RBD IgG antibody was volume diluted 21.3-fold into posttransfusion seronegative recipients from matched donor units. Virus-specific antibody delivered was approximately 1.2 mg. The high-antibody recipients transfused early (symptom onset within 5 days) had no hospitalizations. A CCP-recipient analysis for antibody thresholds correlated to reduced hospitalizations found a statistical significant association between early transfusion and high antibodies versus all other CCP recipients (or control plasma), with antibody cutoffs established by both methods-donor-based virus neutralization cutoffs in posttransfusion recipients (0/85 [0%] versus 15/276 [5.6%]; P = 0.03) or ROC-based cutoff (0/94 [0%] versus 15/267 [5.4%]; P = 0.01).CONCLUSIONIn unvaccinated, seronegative CCP recipients, early transfusion of plasma units in the upper 30% of study donors' antibody levels reduced outpatient hospitalizations. High antibody level plasma units, given early, should be reserved for therapeutic use.TRIAL REGISTRATIONClinicalTrials.gov NCT04373460.FUNDINGDepartment of Defense (W911QY2090012); Defense Health Agency; Bloomberg Philanthropies; the State of Maryland; NIH (3R01AI152078-01S1, U24TR001609-S3, 1K23HL151826NIH); the Mental Wellness Foundation; the Moriah Fund; Octapharma; the Healthnetwork Foundation; the Shear Family Foundation; the NorthShore Research Institute; and the Rice Foundation.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
JCI insight - 9(2024), 8 vom: 14. März |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.04.2024 Date Revised 25.04.2024 published: Electronic ClinicalTrials.gov: NCT04373460 UpdateOf: medRxiv. 2023 Dec 15;:. - PMID 37131659 Citation Status MEDLINE |
|---|
| doi: |
10.1172/jci.insight.178460 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369732375 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369732375 | ||
| 003 | DE-627 | ||
| 005 | 20240425233144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/jci.insight.178460 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM369732375 | ||
| 035 | |a (NLM)38483534 | ||
| 035 | |a (PII)e178460 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Park, Han-Sol |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04373460 | ||
| 500 | |a UpdateOf: medRxiv. 2023 Dec 15;:. - PMID 37131659 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUNDCOVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined.METHODSThis secondary analysis correlated donor and recipient antibody levels to hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double-blind, randomized clinical trial that compared CCP to control plasma. The majority of COVID-19 CCP arm hospitalizations (15/17, 88%) occurred in this unvaccinated, seronegative subgroup. A functional cutoff to delineate recipient high versus low posttransfusion antibody levels was established by 2 methods: (i) analyzing virus neutralization-equivalent anti-Spike receptor-binding domain immunoglobulin G (anti-S-RBD IgG) responses in donors or (ii) receiver operating characteristic (ROC) curve analysis.RESULTSSARS-CoV-2 anti-S-RBD IgG antibody was volume diluted 21.3-fold into posttransfusion seronegative recipients from matched donor units. Virus-specific antibody delivered was approximately 1.2 mg. The high-antibody recipients transfused early (symptom onset within 5 days) had no hospitalizations. A CCP-recipient analysis for antibody thresholds correlated to reduced hospitalizations found a statistical significant association between early transfusion and high antibodies versus all other CCP recipients (or control plasma), with antibody cutoffs established by both methods-donor-based virus neutralization cutoffs in posttransfusion recipients (0/85 [0%] versus 15/276 [5.6%]; P = 0.03) or ROC-based cutoff (0/94 [0%] versus 15/267 [5.4%]; P = 0.01).CONCLUSIONIn unvaccinated, seronegative CCP recipients, early transfusion of plasma units in the upper 30% of study donors' antibody levels reduced outpatient hospitalizations. High antibody level plasma units, given early, should be reserved for therapeutic use.TRIAL REGISTRATIONClinicalTrials.gov NCT04373460.FUNDINGDepartment of Defense (W911QY2090012); Defense Health Agency; Bloomberg Philanthropies; the State of Maryland; NIH (3R01AI152078-01S1, U24TR001609-S3, 1K23HL151826NIH); the Mental Wellness Foundation; the Moriah Fund; Octapharma; the Healthnetwork Foundation; the Shear Family Foundation; the NorthShore Research Institute; and the Rice Foundation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunoglobulins | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Yin, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Barranta, Caelan |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Caputo, Christopher A |e verfasserin |4 aut | |
| 700 | 1 | |a Sachithanandham, Jaiprasath |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Maggie |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Steve |e verfasserin |4 aut | |
| 700 | 1 | |a Sitaras, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Jedlicka, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Eby, Yolanda |e verfasserin |4 aut | |
| 700 | 1 | |a Ram, Malathi |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez, Reinaldo E |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Owen R |e verfasserin |4 aut | |
| 700 | 1 | |a Shenoy, Aarthi G |e verfasserin |4 aut | |
| 700 | 1 | |a Mosnaim, Giselle S |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuta, Yuriko |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Bela |e verfasserin |4 aut | |
| 700 | 1 | |a Heath, Sonya L |e verfasserin |4 aut | |
| 700 | 1 | |a Levine, Adam C |e verfasserin |4 aut | |
| 700 | 1 | |a Meisenberg, Barry R |e verfasserin |4 aut | |
| 700 | 1 | |a Spivak, Emily S |e verfasserin |4 aut | |
| 700 | 1 | |a Anjan, Shweta |e verfasserin |4 aut | |
| 700 | 1 | |a Huaman, Moises A |e verfasserin |4 aut | |
| 700 | 1 | |a Blair, Janis E |e verfasserin |4 aut | |
| 700 | 1 | |a Currier, Judith S |e verfasserin |4 aut | |
| 700 | 1 | |a Paxton, James H |e verfasserin |4 aut | |
| 700 | 1 | |a Gerber, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Petrini, Joann R |e verfasserin |4 aut | |
| 700 | 1 | |a Broderick, Patrick B |e verfasserin |4 aut | |
| 700 | 1 | |a Rausch, William |e verfasserin |4 aut | |
| 700 | 1 | |a Cordisco, Marie Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Hammel, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Greenblatt, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Cluzet, Valerie C |e verfasserin |4 aut | |
| 700 | 1 | |a Cruser, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Oei, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Abinante, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Hammitt, Laura L |e verfasserin |4 aut | |
| 700 | 1 | |a Sutcliffe, Catherine G |e verfasserin |4 aut | |
| 700 | 1 | |a Forthal, Donald N |e verfasserin |4 aut | |
| 700 | 1 | |a Zand, Martin S |e verfasserin |4 aut | |
| 700 | 1 | |a Cachay, Edward R |e verfasserin |4 aut | |
| 700 | 1 | |a Raval, Jay S |e verfasserin |4 aut | |
| 700 | 1 | |a Kassaye, Seble G |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Christi E |e verfasserin |4 aut | |
| 700 | 1 | |a Yarava, Anusha |e verfasserin |4 aut | |
| 700 | 1 | |a Lane, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a McBee, Nichol A |e verfasserin |4 aut | |
| 700 | 1 | |a Gawad, Amy L |e verfasserin |4 aut | |
| 700 | 1 | |a Karlen, Nicky |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Atika |e verfasserin |4 aut | |
| 700 | 1 | |a Ford, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Jabs, Douglas A |e verfasserin |4 aut | |
| 700 | 1 | |a Appel, Lawrence J |e verfasserin |4 aut | |
| 700 | 1 | |a Shade, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Bryan |e verfasserin |4 aut | |
| 700 | 1 | |a Ehrhardt, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Baksh, Sheriza N |e verfasserin |4 aut | |
| 700 | 1 | |a Shapiro, Janna R |e verfasserin |4 aut | |
| 700 | 1 | |a Ou, Jiangda |e verfasserin |4 aut | |
| 700 | 1 | |a Na, Yu Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Knoll, Maria D |e verfasserin |4 aut | |
| 700 | 1 | |a Ornelas-Gatdula, Elysse |e verfasserin |4 aut | |
| 700 | 1 | |a Arroyo-Curras, Netzahualcoyotl |e verfasserin |4 aut | |
| 700 | 1 | |a Gniadek, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a Caturegli, Patrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jinke |e verfasserin |4 aut | |
| 700 | 1 | |a Ndahiro, Nelson |e verfasserin |4 aut | |
| 700 | 1 | |a Betenbaugh, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Ziman, Alyssa |e verfasserin |4 aut | |
| 700 | 1 | |a Hanley, Daniel F |e verfasserin |4 aut | |
| 700 | 1 | |a Casadevall, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Shoham, Shmuel |e verfasserin |4 aut | |
| 700 | 1 | |a Bloch, Evan M |e verfasserin |4 aut | |
| 700 | 1 | |a Gebo, Kelly A |e verfasserin |4 aut | |
| 700 | 1 | |a Tobian, Aaron Ar |e verfasserin |4 aut | |
| 700 | 1 | |a Laeyendecker, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Pekosz, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Sabra L |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, David J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCI insight |d 2016 |g 9(2024), 8 vom: 14. März |w (DE-627)NLM257703918 |x 2379-3708 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:8 |g day:14 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/jci.insight.178460 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 8 |b 14 |c 03 | ||